DHEA AND KETOCONAZOLE

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。所列机构为中心机构，不一定是研究者机构。这项研究有两个组成部分。第1阶段确定了尽管进行了最佳保守治疗（包括使用适当的血压控制和低蛋白、氨基酸补充饮食）但仍患有进行性慢性肾脏疾病的患者。在第2阶段，尽管采取了这些措施，但肾功能仍进行性下降的患者用200 mg/天的酮康唑加低剂量泼尼松（2.5 mg/天）治疗。目前，2例胰岛素依赖型糖尿病肾病患者继续接受酮康唑加泼尼松治疗，维持独立的肾功能。6例患者在研究的第1阶段继续接受随访，并继续显示稳定的肾功能。另外3例新患者入组I期。1例患者在初始评估时发生了非常晚期的肾衰竭，并迅速进展为透析。另外两名患者目前正在接受随访，以评估其肾衰竭的进展程度。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study has 2 components. Phase 1 identifies patients who have progressive chronic kidney disease despite optimal conservative management including the use of adequate blood pressure control and a low protein, amino acid supplemented diet. In phase 2 those patients with a progressive decrease in kidney function despite these measures are treated with 200 mg/day of ketoconazole plus low dose prednisone (2.5 mg/day). Currently two patients with insulin-dependent diabetes mellitus and nephropathy continue to receive ketoconazole plus prednisone and maintain independent renal function. Six patients continue to be followed in phase 1 of the study and continue to show stable renal function. Three additional new patients were entered into Phase 1. One had very advanced kidney failure at the time of initial assessment and rapidly progressed to dialysis. The other two are currently being followed to assess the degree of progression of their kidney failure.